SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Fidelity Advisor Biotechnology Fund Class A (FBTAX) trades at a trailing P/E of 11.1. Trailing earnings yield is 9.03%. PEG 0.70 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — P/E is below market average (11.1); PEG ≤ 1.0 — Peter Lynch undervalued (0.70); earnings yield beats bond yields (9.03%).
- PEG Ratio 0.70 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 9.03% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
Overall SharesGrow Score: 81/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — FBTAX
Valuation Multiples
P/E (TTM)11.1
Forward P/EN/A
PEG Ratio0.70
Forward PEGN/A
P/B Ratio0.00
P/S Ratio1.20
EV/EBITDA0.0
Per Share Data
EPS (TTM)$3.65
Book Value / Share$0.00
Revenue / Share$33.59
FCF / Share$0.00
Yields & Fair Value
Earnings Yield9.03%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2014 |
$0.81 |
$392.35M |
$13.92M |
3.5% |
| 2015 |
$1.59 |
$377.69M |
$26.83M |
7.1% |
| 2016 |
$0.09 |
$364.2M |
$1.35M |
0.4% |
| 2017 |
$-0.68 |
$362.68M |
$-10.14M |
-2.8% |
| 2018 |
$-1.23 |
$336.59M |
$-17.93M |
-5.3% |
| 2019 |
$0.02 |
$338.54M |
$261K |
0.1% |
| 2020 |
$-1.54 |
$255.31M |
$-22.98M |
-9% |
| 2021 |
$2.93 |
$411.52M |
$47.27M |
11.5% |
| 2022 |
$3.15 |
$467.94M |
$47.99M |
10.3% |
| 2023 |
$3.65 |
$486.11M |
$52.81M |
10.9% |
